Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Amortizatization of Intangibles (2016 - 2024)

Historic Amortizatization of Intangibles for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q1 2024 value amounting to $22000.0.

  • Lineage Cell Therapeutics' Amortizatization of Intangibles fell 3333.33% to $22000.0 in Q1 2024 from the same period last year, while for Dec 2024 it was $22000.0, marking a year-over-year decrease of 8307.69%. This contributed to the annual value of $22000.0 for FY2024, which is 8307.69% down from last year.
  • Lineage Cell Therapeutics' Amortizatization of Intangibles amounted to $22000.0 in Q1 2024, which was down 3333.33% from $32000.0 recorded in Q4 2023.
  • In the past 5 years, Lineage Cell Therapeutics' Amortizatization of Intangibles ranged from a high of $498000.0 in Q1 2020 and a low of $22000.0 during Q1 2024
  • Its 5-year average for Amortizatization of Intangibles is $101117.6, with a median of $33000.0 in 2021.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first tumbled by 9009.01% in 2021, then skyrocketed by 4545.45% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Amortizatization of Intangibles (Quarter) stood at $136000.0 in 2020, then crashed by 76.47% to $32000.0 in 2021, then changed by 0.0% to $32000.0 in 2022, then changed by 0.0% to $32000.0 in 2023, then crashed by 31.25% to $22000.0 in 2024.
  • Its Amortizatization of Intangibles was $22000.0 in Q1 2024, compared to $32000.0 in Q4 2023 and $33000.0 in Q3 2023.